ARVO

Presenters from around the world converge on the Pacific Northwest to highlight innovation.

At this year's ARVO meeting, Michael Chaglasian, OD, spoke with Ophthalmology Times about the paper he presented on the detection of glaucoma with a novel widefield imaging device combined with OCT

At this year's ARVO meeting, Irene Santiago Tierno, MS, talked with Ophthalmology Times about the paper she presented on how abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early age-related macular degeneration.

At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in Diabetic macular edema.

At this year's ARVO meeting, Edmund Tsui, MD, presented a paper on the analysis of anterior chamber inflammation through automated quantitative assessment of swept-source anterior segment OCT images.

At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.

This year at ARVO, Anand Swaroop, PhD, was awarded the Friedenwald Award Lecture 2024. He spoke with the Eye Care Network about this lecture and what the award meant to him.

This year at ARVO, Emily Chew, MD, was awarded the Proctor Award Lecture. She spoke with the Eye Care Network about this lecture and what the award meant to her.

This year at ARVO, Daniel Saban PhD, was awarded the Cogan Award Lecture. He spoke with the Eye Care Network about this lecture and what the award meant to him.

At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.

At this year's ARVO meeting in Seattle, Washington, Dolly Chang, MD, PhD, presented data on the early fluid reduction in patients with diabetic macular edema, and how that correlates with 1-year outcome with a deep learning-based retina segmentation tool using the Phase 2 BOULEVARD trial.

At this year's ARVO meeting, Allen Ho, MD, presented a paper on the 12-month results of a mutation agnostic optogenetic program for patients with severe vision loss from retinitis pigmentosa.

At this year's ARVO meeting, Deborah A. Ferrington, PhD, presented "Genotype-specific differences in mitochondrial function specific to the CFH Y402H risk allele associated with AMD."

SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."

An analysis showed an association between patients who previously had undergone intravitreal injections and cataract surgery and a higher risk of the development of a non-clearing vitreous hemorrhage, retinal detachment, retinal tear, and glaucoma surgery.

Elias Kahan, MD, speaks about wide-field contact specular microscopy and the expanding scope of corneal endothelial research.

Pucker shares topline results from a study that investigated the difference in meibomobian gland morphology when measured with a Visante OCT versus an OCULUS Keratograph 5M

Voretigene neparvovec (Luxturna, Spark Therapeutics, Inc.) was shown to be safe and effective in real-world settings.

Huntington's disease (HD) is an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age.

In a conversation with the Eye Care Network at ARVO, Osamah Saeedi, MD, MS, Associate Professor of Ophthalmology, Director of Clinical Research and Director of the Glaucoma Division at the University of Maryland School of Medicine, explained the key findings from his poster.

Tylectomy indicates surgical resection of retinoblastomas via pars plana vitrectomy with intraoperative chemotherapy infusion.

Dustin Morley, PhD, principal research scientist at LENSAR, discusses research on applying deep learning to benefit FLACS procedures.

Sadda discusses his goals for ARVO, focusing on enhancing the organization's role in promoting scientific exchange in vision research. He underscores the significance of the annual meetings for networking and driving innovation in ophthalmology.

In a conversation with the Eye Care Network at ARVO, Corradetti, a research scientist at Doheny Eye Institute, explained the key findings from her work.

Four poster presentations at the Association for Research in Vision and Ophthalmology’s (ARVO) 2024 Annual Meeting in Seattle, Washington, demonstrate the possibilities.

Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9, on a multi-ingredient oral supplement on dry eye symptoms and tear volume.

John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Eric Donnenfeld, MD, sat down to discuss presentations on the novel new artificial tear, Blink Triple Care, about its efficacy in a non-controlled trial as well as comparison to the Classic Blink at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.